Literature DB >> 24405842

Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-α.

Angeline Gradolatto1, Dani Nazzal2, Frédérique Truffault3, Jacky Bismuth4, Elie Fadel5, Maria Foti6, Sonia Berrih-Aknin7.   

Abstract

Myasthenia gravis (MG) is an autoimmune disease in which the thymus frequently presents follicular hyperplasia and signs of inflammation and T cells display a defect in suppressive regulation. Defects in a suppressive assay can indicate either the defective function of Treg cells or the resistance of Tconv cells to suppression by Treg cells. The aim of this study was to determine which cells were responsible for this defect and to address the mechanisms involved. We first performed cross-experiment studies using purified thymic Treg cells and Tconv cells from controls (CTRL) and MG patients. We confirmed that MG Treg cells were defective in suppressing CTRL Tconv proliferation, and we demonstrated for the first time that MG Tconv cells were resistant to Treg cell suppression. The activation of MG Tconv cells triggered a lower upregulation of FoxP3 and a higher upregulation of CD4 and CD25 than CTRL cells. To investigate the factors that could explain these differences, we analyzed the transcriptomes of purified thymic Treg and Tconv cells from MG patients in comparison to CTRL cells. Many of the pathways revealed by this analysis are involved in other autoimmune diseases, and T cells from MG patients exhibit a Th1/Th17/Tfh signature. An increase in IL-17-related genes was only observed in Treg cells, while increases in IFN-γ, IL-21, and TNF-α were observed in both Treg and Tconv cells. These results were confirmed by PCR studies. In addition, the role of TNF-α in the defect in Tconv cells from MG patients was further confirmed by functional studies. Altogether, our results indicate that the immunoregulatory defects observed in MG patients are caused by both Treg cell and Tconv cell impairment and involve several pro-inflammatory cytokines, with TNF-α playing a key role in this process. The chronic inflammation present in the thymus of MG patients could provide an explanation for the escape of thymic T cells from regulation in the MG thymus.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic inflammation; IL-17; TNF-α; Tconv cells; Thymus; Treg cells

Mesh:

Substances:

Year:  2014        PMID: 24405842     DOI: 10.1016/j.jaut.2013.12.015

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  43 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.

Authors:  Muriel Sudres; Marie Maurer; Marieke Robinet; Jacky Bismuth; Frédérique Truffault; Diane Girard; Nadine Dragin; Mohamed Attia; Elie Fadel; Nicola Santelmo; Camille Sicsic; Talma Brenner; Sonia Berrih-Aknin
Journal:  JCI Insight       Date:  2017-04-06

Review 3.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

4.  Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.

Authors:  H-W Yang; P Lei; Y-C Xie; Z-L Han; D Li; S-H Wang; Z-L Sun
Journal:  Cancer Gene Ther       Date:  2017-04-21       Impact factor: 5.987

Review 5.  [True thymic hyperplasia : Differential diagnosis of thymic mass lesions in neonates and children].

Authors:  C-A Weis; B Märkl; T Schuster; K Vollert; P Ströbel; A Marx
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 6.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

7.  Transcriptional repressor Blimp1 regulates follicular regulatory T-cell homeostasis and function.

Authors:  Guang Yang; Xiaosu Yang; Junmei Zhang; Guancheng Li; Dandan Zheng; Anjiao Peng; Jue Hu; Liqun Xu; Baifeng Yang; Huan Yang; Wenbin Zhou; Erdem Tuzun; Jing Li
Journal:  Immunology       Date:  2017-10-19       Impact factor: 7.397

8.  Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.

Authors:  Ruoyi Jiang; Kenneth B Hoehn; Casey S Lee; Minh C Pham; Robert J Homer; Frank C Detterbeck; Inmaculada Aban; Leslie Jacobson; Angela Vincent; Richard J Nowak; Henry J Kaminski; Steven H Kleinstein; Kevin C O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

9.  Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis.

Authors:  John S Yi; Melissa A Russo; Shruti Raja; Janice M Massey; Vern C Juel; Jay Shin; Lisa D Hobson-Webb; Karissa Gable; Jeffrey T Guptill
Journal:  Exp Neurol       Date:  2019-12-12       Impact factor: 5.330

10.  The effect of interleukin (IL)-21 and CD4+ CD25++ T cells on cytokine production of CD4+ responder T cells in patients with myasthenia gravis.

Authors:  M Alahgholi-Hajibehzad; H Durmuş; F Aysal; Y Gülşen-Parman; P Oflazer; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2017-07-28       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.